- Home
- ILMN vs MTZ Comparison
ILMN vs MTZ Comparison
Compare ILMN & MTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILMN | MTZ |
|---|---|---|
| Founded | 1998 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 17.4B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | ILMN | MTZ |
|---|---|---|
| Price | $137.60 | $223.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 20 |
| Target Price | $116.19 | ★ $231.37 |
| AVG Volume (30 Days) | ★ 1.8M | 836.8K |
| Earning Date | 02-05-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 270.77 |
| EPS | ★ 4.46 | 4.20 |
| Revenue | $4,288,000,000.00 | ★ $13,762,473,000.00 |
| Revenue This Year | N/A | $15.48 |
| Revenue Next Year | $2.08 | $10.21 |
| P/E Ratio | ★ $30.22 | $51.98 |
| Revenue Growth | N/A | ★ 12.99 |
| 52 Week Low | $68.70 | $99.70 |
| 52 Week High | $153.06 | $233.14 |
Technical Indicators
Market Signals| Indicator | ILMN | MTZ |
|---|---|---|
| Relative Strength Index (RSI) | 67.61 | 58.98 |
| Support Level | $129.29 | $206.15 |
| Resistance Level | $137.09 | $233.14 |
| Average True Range (ATR) | 3.94 | 8.59 |
| MACD | -0.37 | -0.44 |
| Stochastic Oscillator | 91.74 | 64.95 |
Price Performance
Historical ComparisonAbout ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.